Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

GLP-1s are basically appetite’s off-switch: suddenly you’re “full” after three bites. Congrats on the smaller meals and ...

As blockbuster GLP-1 injectables like Mounjaro, Wegovy and Ozempic gain traction in India, doctors stress that careful ...

The discussion surrounding GLP-1 medications needs to change to one that emphasizes science-based research and compassion.

Since we know that eating less food often means getting fewer nutrients, a high-quality multivitamin acts as an insurance ...

GLP-1 receptor agonists like semaglutide and tirzepatide have redefined what’s possible in the treatment of obesity and metabolic syndrome. These medications have shown remarkable results in appetite ...

Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity ...

Our work continues on behalf of TRICARE For Life beneficiaries. Learn the latest, and find out how to share your story with ...

GLP-1 drugs like Ozempic and Mounjaro have significant health benefits for type 1 diabetes, including weight loss, despite ...

The MarketWatch News Department was not involved in the creation of this content. Studies presented at Obesity Week 2025 validate the test's ability to predict weight-loss response to GLP-1 drugs like ...